EGFR and non-small cell lung carcinoma: To validate that digital CATCH is capable of detecting drug resistance gene mutations, we tested 76 plasma samples from 76 NSCLC patients treated with first-line EGFR-TKI, and compared the results from digital CATCH with gold-standard deep sequencing (CAPP-Seq) technique (Fig. 5C).